USPTO Examiner DRAPER LESLIE A ROYDS - Art Unit 1629

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19244143COMBINATION THERAPY FOR A DOPAMINE AGONISTJune 2025December 2025Allow520YesNo
19074260COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITYMarch 2025July 2025Allow410NoNo
19024972INHIBITORS OF MPTPJanuary 2025July 2025Allow611NoNo
18811355USE OF GLUTAMATE 2B RECEPTOR ANTAGONISTS AND SIGMA RECEPTOR AGONISTS AS ANTITUSSIVESAugust 2024September 2025Allow1321NoNo
18727731USE OF ANTI-IDIOPATHIC PULMONARY FIBROSIS DRUG NINTEDANIB IN TREATMENT OF TUBERCULOSISAugust 2024February 2026Abandon2020NoNo
18660997AGENT FOR REDUCING VISCERAL FAT WEIGHTMay 2024June 2025Abandon1310NoNo
18658542TREATMENT OF CANCER USING ORGANOARSENICALSMay 2024May 2025Allow1221NoNo
18691696MITOCHONDRIAL THERAPEUTIC AGENTSMarch 2024July 2025Allow1610YesNo
18423029METHODS FOR TREATING CHOLESTASISJanuary 2024April 2025Allow1540YesNo
18421934THIAZOLIDINEDIONE ANALOGS FOR THE TREATMENT OF NAFLD AND METABOLIC DISEASESJanuary 2024December 2024Abandon1111NoNo
18395982PYRAZINO[2',1':2,3]IMIDAZO[4,5-B][1,7]NAPHTHYRIDINES COMPOUNDS AS CK2 INHIBITORSDecember 2023April 2024Allow411NoNo
18537765COMPOSITIONS AND METHODS FOR TREATING, PREVENTING OR REVERSING AGE-ASSOCIATED INFLAMMATION AND DISORDERDecember 2023March 2025Allow1611YesNo
18515252CROMOLYN METAL COMPLEXES AS ENHANCED PHARMACEUTICAL FORMULATIONS AND METHOD OF USING THE SAMENovember 2023March 2025Abandon1610NoNo
18502460ORGANIC COMPOUNDSNovember 2023June 2025Allow1920NoNo
18378976COMPOSITIONS AND METHODS FOR TREATING SEVERE CONSTIPATIONOctober 2023March 2025Allow1710NoNo
18482872REMEDIATION OF ALL DISEASES CAUSED BY RADIATION RELATED REACTIVE ION SPECIES ARE ALL CORRECTABLE BY H2S - SO2 GENERATED BY FDA-STS SODIUM THIOSULFATE, NA2S203October 2023May 2025Abandon1921NoNo
18363848SUSPENSION FOR ORAL ADMINISTRATION COMPRISING AMORPHOUS TOLVAPTANAugust 2023February 2025Abandon1910NoNo
18207668ADMINISTRATION OF N,N-DIMETHYLACETAMIDE AND ITS MONOMETHYLATED METABOLITES FOR THE TREATMENT OF INFLAMMATORY DISORDERSJune 2023February 2025Abandon2101NoNo
18322909AGENT FOR REDUCING VISCERAL FAT WEIGHTMay 2023June 2024Abandon1310NoNo
18195921COMMIPHORA MYRRHA RESIN EXTRACT WITH NON-COVALENTLY ASSOCIATED VITAMIN B1 AND VITAMIN C COMPOUNDSMay 2023May 2025Abandon2541NoNo
18137925TABLET FORMULATION FOR CGRP ACTIVE COMPOUNDSApril 2023December 2024Abandon2011YesNo
18137919METHODS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASEApril 2023January 2024Allow910YesNo
18137922METHODS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASEApril 2023December 2024Allow2020YesNo
17976710TREATMENT OF AUTOIMMUNE DISEASEOctober 2022March 2024Abandon1610NoNo
18047932CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONSOctober 2022November 2023Abandon1320NoYes
17960669METHODS FOR TREATING CHOLESTASISOctober 2022November 2023Allow1330YesNo
17937994CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONSOctober 2022May 2024Abandon1930NoNo
17937990CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONSOctober 2022February 2023Allow410NoNo
17995031CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONSSeptember 2022February 2026Abandon4120NoNo
17953036METHODS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASESeptember 2022December 2023Abandon1410NoNo
17902119AGENT FOR REDUCING VISCERAL FAT WEIGHTSeptember 2022July 2023Abandon1010NoNo
17802949COMPOSITIONS AND USES THEREOFAugust 2022July 2025Abandon3510YesNo
17887270COMBINATION COMPOSITIONS FOR IMMUNOTHERAPYAugust 2022June 2024Abandon2211NoNo
17866724METHOD AND COMPOSITIONS FOR FORMING A COPPER-CONTAINING COMPLEX AND USES THEREOFJuly 2022September 2024Allow2610YesNo
178665143-TRIAZOLYL METHYL-1,3,5-TRIAZINE-2,4-DIONE COMPOUNDS AND PREPARATION METHOD AND APPLICATION THEREOFJuly 2022December 2022Allow510NoNo
17866437ANTITHROMBOTIC COMPOSITIONS AND METHODS FOR USING SAMEJuly 2022April 2025Allow3340NoNo
17860682CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONSJuly 2022September 2022Allow310NoNo
17833131METHOD AND COMPOSITIONS FOR USE IN PROVIDING MALE CONTRACEPTIONJune 2022April 2024Abandon2231NoNo
17778369COMPOSITIONS AND METHODS FOR TREATING, PREVENTING OR REVERSING AGE-ASSOCIATED INFLAMMATION AND DISORDERSMay 2022March 2025Allow3421YesNo
17771664Use of Glutamate 2B Receptor Antagonists and Sigma Receptor Agonists as AntitussivesApril 2022July 2025Allow3831YesYes
17770932Pharmaceutical Composition for Protecting CartilageApril 2022February 2026Abandon4601NoNo
17717140USE OF POTASSIUM CHANNEL INHIBITOR FOR TREATING DEPRESSIONApril 2022May 2025Abandon3821NoNo
17654061TOPICAL DAPSONE AND DAPSONE/ADAPALENE COMPOSITIONS AND METHODS FOR USE THEREOFMarch 2022June 2023Abandon1610NoNo
17687929PHARMACEUTICAL COMPOSITION CONTAINING HDAC6 INHIBITOR AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF ITCHINGMarch 2022June 2023Abandon1510NoNo
17673136PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF INSOMNIAFebruary 2022June 2023Allow1631YesNo
17587543TREATMENT OF INFLAMMATORY SKIN CONDITIONSJanuary 2022November 2025Abandon4601NoNo
17572368AMINO ACID DELIVERY SYSTEMJanuary 2022March 2023Abandon1420YesNo
17565584COMPOSITIONS AND METHODS FOR TREATING SEVERE CONSTIPATIONDecember 2021July 2023Allow1820YesNo
17554588METHODS FOR TREATING CHOLESTASISDecember 2021August 2022Allow820YesNo
17643145COMPOSITIONS FOR RETARDING THE DECOMPOSITION OF MELATONIN IN SOLUTIONDecember 2021July 2025Abandon4311NoNo
17595332QUINAZOLINE-2,4-DIONE DERIVATIVES AS PARP INHIBITORSNovember 2021December 2025Allow4921YesNo
17519916STABLE CANNABINOID FORMULATIONSNovember 2021February 2024Abandon2801NoNo
17607868Use of R-enantiomer Beta2-agonists for prevent and treatment of pulmonary inflammation and inflammatory remodeling for reduced adverse effectsOctober 2021July 2023Abandon2120NoNo
17607475METHOD FOR TREATING ENDOMETRIOSIS-ASSOCIATED PAIN BY USING DIAMINOPYRIMIDINE COMPOUNDOctober 2021December 2025Allow5021YesNo
17479382Crystalline Form of y-Aminobutyric Acid AnalogSeptember 2021December 2023Abandon2601NoNo
17472882IDENTIFICATION OF AGENTS DISPLAYING FUNCTIONAL ACTIVATION OF DOPAMINE D2 AND D4 RECEPTORSSeptember 2021May 2023Abandon2010NoNo
17466366COMPOSITIONS COMPRISING FUSIDIC ACID AND PACKAGES THEREFORSeptember 2021May 2023Abandon2030NoNo
17375087Methods of Treating AscitesJuly 2021August 2024Allow3731NoNo
17353681SUBSTITUTED BIARYL SULFONAMIDES AND THE USE THEREOFJune 2021March 2023Allow2110NoNo
17347253SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USEJune 2021February 2026Abandon5631NoNo
17335407NMDA RECEPTOR ANTAGONIST FORMULATION WITH REDUCED NEUROTOXICITYJune 2021October 2023Abandon2901NoNo
17330987CONCOMITANT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATOR RELACORILANT AND CYP2C9 SUBSTRATESMay 2021February 2026Allow5751NoNo
17320977COMPOSITIONS COMPRISING OMEGA-3 FATTY ACIDS, 17-HDHA AND 18-HEPE AND METHODS OF USING SAMEMay 2021July 2023Allow2710NoNo
17307208Cromolyn Metal Complexes as enhanced pharmaceutical formulations and method of preparing the sameMay 2021August 2023Allow2720NoNo
17244319Method of Treating AscitesApril 2021September 2022Abandon1610NoNo
17238409BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORSApril 2021January 2023Allow2110NoNo
17237137METHOD OF TREATING CANCERApril 2021February 2025Allow4620NoNo
17232254Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis RateApril 2021July 2024Abandon3921NoNo
17285432PYRROLO-PYRIDAZINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORSApril 2021August 2024Allow4010NoNo
17226781COMPOSITION FOR BLOCKING ANGIOGENESISApril 2021January 2023Allow2201YesNo
17186651INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK)February 2021October 2024Abandon4401NoNo
17271793O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOFFebruary 2021November 2025Allow5731YesNo
17186226AGENT FOR REDUCING VISCERAL FAT WEIGHTFebruary 2021October 2022Abandon2010NoNo
17268440INHIBITORS TO TARGET HIV-1 NEF-CD80/CD86 INTERACTIONS FOR THERAPEUTIC INTERVENTIONFebruary 2021June 2023Abandon2801NoNo
17168291Arginase Inhibitors and Their Therapeutic ApplicationsFebruary 2021March 2024Allow3721YesNo
171643914-HYDROXYBUTYRIC ACID ANALOGSFebruary 2021September 2024Abandon4421NoNo
17156125FORMULATIONS WITH REDUCED DEGRADATION OF POLYSORBATEJanuary 2021December 2025Abandon5940NoNo
17137665NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOFDecember 2020August 2023Allow3120YesNo
17110398TABLET FORMULATION FOR CGRP ACTIVE COMPOUNDSDecember 2020November 2023Allow3551NoNo
17100721Method to Identify Agents That Can Overcome Inhibition Caused By Drug-protein Binding of the Human Plasma Protein, Alpha-1-acid GlycoproteinNovember 2020August 2023Abandon3321NoNo
170554821,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH NERVE FIBER SENSITIZATIONNovember 2020May 2024Abandon4201NoNo
17094405NOVEL PHARMACEUTICAL COMPOSITIONS AND METHODS FOR MENOPAUSE RELATED ANXIETY AND DEPRESSIONNovember 2020October 2022Abandon2431NoNo
17047800SUSTAINED RELEASE PYRIDOSTIGMINE COMPOSITIONSNovember 2020September 2025Allow5921NoNo
17083783METHODS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING RELAPSE IN A PERSON WITH AN ADDICTION USING BETA ADRENERGIC RECEPTOR ANTAGONIST AND MUSCARINIC RECEPTOR ANTAGONIST COMBINATIONSOctober 2020June 2023Abandon3211NoNo
17072809METHODS OF TREATING NEURODEGENERATIVE DISEASES USING INDANE ACETIC ACID DERIVATIVES WHICH PENETRATE THE BLOOD BRAIN BARRIEROctober 2020September 2025Abandon5930YesNo
17070401COMPOSITIONS COMPRISING OMEGA-3 FATTY ACIDS, 17-HDHA AND 18-HEPE AND METHODS OF USING SAMEOctober 2020March 2021Allow510YesNo
17047479ENHANCEMENT OF DELIVERY OF LIPOPHILIC ACTIVE AGENTS ACROSS THE BLOOD-BRAIN BARRIER AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERSOctober 2020September 2023Abandon3501NoNo
17068552COMBINATION COMPOSITIONS FOR IMMUNOTHERAPYOctober 2020September 2022Abandon2311NoNo
17066033BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTSOctober 2020June 2022Abandon2010NoNo
17015883ORGANIC COMPOUNDSSeptember 2020August 2023Allow3521YesNo
17009457MELATONIN AGONIST TREATMENTSeptember 2020April 2022Abandon1910NoNo
16994368METHODS FOR TREATING CHOLESTASISAugust 2020April 2021Allow841YesNo
16991726HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASKAugust 2020May 2022Allow2110NoNo
16943323METHOD OF TREATING CANCERJuly 2020October 2022Abandon2610NoNo
16961302PHARMACEUTICAL COMPOSITION CONTAINING HDAC6 INHIBITOR AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF ITCHINGJuly 2020September 2022Abandon2620YesNo
16924905BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORSJuly 2020January 2021Allow610YesNo
16913927COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE AND PARKINSON'S DISEASEJune 2020March 2022Allow2151NoNo
16910786METHOD FOR TREATING PROTEIN AGGREGATION DISEASESJune 2020July 2022Abandon2421NoNo
16956024AGENTS FOR TREATING CANCER AND METHODS FOR IDENTIFYING SAID AGENTSJune 2020September 2023Abandon3911NoNo
16900498SALTS OF AN LSD1 INHIBITORJune 2020July 2022Allow2520NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DRAPER, LESLIE A ROYDS.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
25
Examiner Affirmed
19
(76.0%)
Examiner Reversed
6
(24.0%)
Reversal Percentile
37.3%
Lower than average

What This Means

With a 24.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
130
Allowed After Appeal Filing
6
(4.6%)
Not Allowed After Appeal Filing
124
(95.4%)
Filing Benefit Percentile
11.7%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 4.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner DRAPER, LESLIE A ROYDS - Prosecution Strategy Guide

Executive Summary

Examiner DRAPER, LESLIE A ROYDS works in Art Unit 1629 and has examined 708 patent applications in our dataset. With an allowance rate of 26.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 36 months.

Allowance Patterns

Examiner DRAPER, LESLIE A ROYDS's allowance rate of 26.0% places them in the 3% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by DRAPER, LESLIE A ROYDS receive 2.52 office actions before reaching final disposition. This places the examiner in the 73% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by DRAPER, LESLIE A ROYDS is 36 months. This places the examiner in the 34% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +49.5% benefit to allowance rate for applications examined by DRAPER, LESLIE A ROYDS. This interview benefit is in the 93% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 9.3% of applications are subsequently allowed. This success rate is in the 4% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 24.1% of cases where such amendments are filed. This entry rate is in the 32% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 11.1% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 24% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 53.7% of appeals filed. This is in the 24% percentile among all examiners. Of these withdrawals, 62.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 61.6% are granted (fully or in part). This grant rate is in the 66% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.6% of allowed cases (in the 61% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.3% of allowed cases (in the 78% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.